Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | See Remarks | December 11, 2023 | December 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date December 11, 2023 · Filed December 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,500 |
Reported balance
After 2023-12-11 transaction · row 1
1 source rowRow 1 · 2023-12-11 · Exercise / conversion · Acquired 14,000 · Balance 77,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 · Expires 2029-12-19 | Direct | 22,427 |
Reported balance
After 2023-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-11 · Exercise / conversion · Disposed 14,000 · Balance 22,427 F1: These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2023 Filed Dec 11, 2023 16:56 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-058082 · doc4.xml · derivative · entry 2 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,427 Underlying: Common Stock · 14,000 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 16:56 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 14,000 | $0.14 | $1,960.00 |
DisclosureSEC source: 0001209191-23-058082 · doc4.xml · nonDerivative · entry 1 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 16:55 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-056086 · doc4.xml · derivative · entry 2 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,427 Underlying: Common Stock · 15,000 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 16:55 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 15,000 | $0.14 | $2,100.00 |
DisclosureSEC source: 0001209191-23-056086 · doc4.xml · nonDerivative · entry 1 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 17:42 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 1 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-22-003785 · doc4.xml · derivative · entry 4 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,427 Underlying: Common Stock · 1 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 17:42 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 1,714 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001209191-22-003785 · doc4.xml · derivative · entry 3 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,857 Underlying: Common Stock · 1,714 shares Expires 2030-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 20% of the total shares subject to the stock option grant vested on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 17:42 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 1 | $0.14 | $0.14 |
DisclosureSEC source: 0001209191-22-003785 · doc4.xml · nonDerivative · entry 2 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 17:42 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 1,714 | $0.21 | $359.94 |
DisclosureSEC source: 0001209191-22-003785 · doc4.xml · nonDerivative · entry 1 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 17:48 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-055530 · doc4.xml · derivative · entry 1 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 19:30 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 12,500 | $8.00 | $100,000.00 |
DisclosureSEC source: 0001209191-21-048082 · doc4.xml · nonDerivative · entry 1 Rhode Peter · CIK 0001866276 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,785 F1 · shares: Represents shares of Common Stock purchased in connection with the Issuer's initial public offering for consideration of $8.00 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.